From Nasdaq: 2025-02-08 23:59:20

4D Molecular Therapeutics (FDMT) shared positive interim data from the Phase 2b PRISM trial, showcasing the efficacy of 4D-150 in treating wet AMD. Patients experienced an 83% reduction in injection burden and many required minimal supplemental injections. Aflibercept expression remained stable for up to two years. In the subgroup resembling Phase 3 patients, 87% needed 0-1 supplemental injections. The drug’s durability and tolerability were consistent across all cohorts, with follow-up extending up to three years. These results offer promising insights into the treatment of wet AMD.



Read more at Nasdaq: 4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMD